First published in 2010, the EULAR recommendations for the management of RA, the most frequent inflammatory rheumatic disease ...

A study looked at more than 23,600 Medicare beneficiaries with RA who had received a ≥30-day prescription of an opioid drug. Participants were grouped according to those who had been prescribed a ...

Please provide your email address to receive an email when new articles are posted on . Demographic factors were significantly associated with slower or faster initiation of b/ts DMARDs for RA.

Please provide your email address to receive an email when new articles are posted on . Patients with RA who responded to DMARD therapy showed reduced microbiome levels of certain bacteria. DMARD ...

A cross-sectional study finds that patients with rheumatoid arthritis receiving disease-modifying antirheumatic drugs (DMARDs) exhibit a reduced immune response to the COVID-19 vaccine compared with ...

Only a decade ago, prior to the availability of anti-TNF agents and other BRMs, most patients with RA were treated with MTX and other DMARDs. Although many patients with RA responded relatively well ...

The European Alliance of Associations for Rheumatology – updated its recommendations on the treatment of rheumatoid arthritis (RA) with disease-modifying antirheumatic drugs (DMARD). The 2025 update ...

Racial-ethnic disparities in care quantity and quality have been well documented throughout medicine. This study focused on rheumatoid arthritis patients' use of disease-modifying anti-rheumatic drugs ...

Weaker immune response against COVID-19 may be attributed to the more targeted immunosuppressive mechanism of biologic DMARDs. Rheumatoid arthritis (RA) patients receiving biologic disease-modifying ...

Rheumatoid arthritis is a chronic autoimmune condition that affects the joints, causing inflammation, stiffness, and pain. Patients searching for popular rheumatoid arthritis prescriptions are often ...

The availability of TNF inhibitor biosimilars and the cost of treating ‘difficult-to-treat’ RA are making first-line TNF inhibition in early RA more attractive in the UK.